—®‹…‘åŠwˆãŠw•”“à•ª”å‘ãŽÓ“à‰È�i‘æ“ñ“à‰È�j‹³Žö
ûü�{�@�M�s
�y—v�@Ž|�z
Ž©ŒÈ–Ɖu�«�b�ó‘B޾г‚ɂ̓oƒZƒhƒE•a‚Æ‹´–{•a‚ª‚ ‚é�B‹´–{•a‚Í�b�ó‘B‹@”\’ቺ �ǂ̌´ˆö‚Å‚ ‚é�B‹´–{•a‚Å‚Í�R�b�ó‘Bƒyƒ‹ƒIƒLƒVƒ_�[ƒ[�R‘Ì�iTPOAb�j‚ ‚é‚¢‚Í�R ƒTƒCƒ�ƒuƒ�ƒuƒŠƒ“�R‘Ì�iTGAb�j‚ª—z�«‚ɂȂé�B‹´–{•a‚Ì�f’f‚Í‘g�D�f�BŽÀ�Û‚É‚Í �R‘ÌTPOAb ‚ ‚é‚¢‚ÍTGAb ‚ª—z�«‚Å‚ ‚ê‚Î�A‹´–{•a‚Æ�f’f�B‹´–{•a‚Ì‘g�D‚Æ�R‘Ì TPOAb �ETGAb ’l‚ð”äŠr‚µ‚½�BTPOAb �ETGAb ‚Ì‹´–{•a�f’f‚ÌŠ´“x�E“ÁˆÙ“x‚Í �‚‚‚͂Ȃ©‚Á‚½�BTPOAb ‚»‚µ‚ÄTGAb ‚Í‹´–{•a‚ÌŒ´ˆö‚ł͂Ȃ�A‹´–{•a‚̂Ƃ«‚É �oŒ»‚·‚é�R�b�ó‘B�R‘̂ł ‚é�B
TSH Žó—e‘Ì�R‘ÌTRAb ‚ɂ͎hŒƒ�R‘ÌTSAb ‚ƃuƒ�ƒbƒLƒ“ƒO�R‘ÌTSBAb ‚ª‚ ‚é�B ƒuƒ�ƒbƒLƒ“ƒO�R‘ÌTSBAb ‚Í�b�ó‘B‹@”\’ቺ�ǂ̌´ˆö‚Å‚ ‚é�BŒoŽž“I‚ÉŽhŒƒ�R‘Ì TSAb ‚©‚çƒuƒ�ƒbƒLƒ“ƒO�R‘ÌTSBAb ‚É�ATSBAb ‚©‚çTSAb ‚ɂȂé—Ⴊ‚ ‚é�B
ŒŸ�¸�GŒŒ’†�b�ó‘Bƒzƒ‹ƒ‚ƒ“�iT4�AT3�A—V—£T4�A—V—£T3�j’á’l�BTSH �‚’l�B TPOAb �ETGAb —z�«�B‚Æ‚«‚ÉTRAb �iTSBAb�j—z�«�B
�f’f�G�b�ó‘BŽî�A”ç•†Š£‘‡�A�™–¬�A”S‰t�…Žî—lŠç–e�BŒŒ’†�b�ó‘Bƒzƒ‹ƒ‚ƒ“’á’l�B TSH �‚’l�BTPOAb �ETGAb —z�«�B‚Æ‚«‚ÉTRAb �iTSBAb�j—z�«�B
Ž¡—Ã�G�b�ó‘Bƒzƒ‹ƒ‚ƒ““Š—^�BT4 “Š—^�B
�b�ó‘B‹@”\’ቺ�ǂ̌´ˆö‚̑啔•ª‚Í‹´–{•a‚Å ‚ ‚é�B‹´–{•a‚ÍŽ©ŒÈ–Ɖu�«–��«�b�ó‘B‰Š�i–��« �b�ó‘B‰Š�j‚Å‚ ‚é�B
‹´–{�ô‚Í4 —á‚Ì’†”N�—�«‚Ì�d‚¢‚т܂ñ�«�b�ó ‘BŽî‚ð‘g�DŠw“I‚ÉŒŸ�õ‚µ�A�‚“xƒŠƒ“ƒp‹…�Z���A ‘@ˆÛ‘��B�A‚»‚µ‚Äàh–E�ã”ç�×–E•Ï�«‚ð”F‚ß�A“Æ —§Ž¾Š³‚Æ‚µ‚½1�j�B‹´–{•a‚ÍŽ©ŒÈ–Ɖu޾г‚Å‚ ‚é�B �b�ó‘Bàh–E�×–E‚ª•Ï�«�EˆÞ�k‚µ�A�b�ó‘B‹@”\’á ‰º�ǂɂȂé�B1�j�‚“xƒŠƒ“ƒp‹…�Z���A2�j‘@ˆÛ‘� �B�A‚»‚µ‚Ä3�jàh–E�ã”ç�×–E•Ï�«�AˆÈ�ã3 ‚‚ª‹´ –{•a�b�ó‘B‚Ì‘g�D�ŠŒ©‚Å‚ ‚é�B1�j2�j3�j‚ɂ͒ö“x ‚Ì�·‚ª‚ ‚é�B—Õ�°“I‚É‚à–³�Ç�ó‚©‚ç�‚“x�b�ó‘B ‹@”\’ቺ�Ç‚ðŽ¦‚·‚à‚̂܂ł ‚é�B�b�ó‘BŽî‚Ì‚Ý ‚Å�b�ó‘B‹@”\‚Í�³�í‚Å‚ ‚é—Ⴊ‘½‚¢�B�‚“x�b�ó ‘B‹@”\’ቺ�ÇŠ³ŽÒ‚Ì�b�ó‘B‚Å‚ÍƒŠƒ“ƒp‹…�Z���A ‘@ˆÛ‘��B�A‚»‚µ‚Äàh–E�ã”ç�×–E•Ï�«‚ð‚Ý‚é�B�b �ó‘Bàh–E�×–E‹@”\‚ª‚È‚¢�B�b�ó‘B‹@”\’ቺ�Ç‚É ‚È‚é�B
‹´–{•a‚ÍŽ©ŒÈ–Ɖu޾г‚Å‚ ‚è�A�b�ó‘B�R‘Ì‚ª —z�«‚ɂȂé�B�b�ó‘B�R‘̂ɂÍ�b�ó‘Bƒyƒ‹ƒIƒLƒV ƒ_�[ƒ[�R‘Ì�iTPOAb�j�AƒTƒCƒ�ƒOƒ�ƒuƒŠƒ“�R‘Ì �iTGAb�j‚ª‚ ‚é�B‹´–{•a‚ÌŠm’è‚Í‘g�D�f’f‚Å ‚ ‚é�BŽÀ�Û‚É‚ÍTPOAb ‚ ‚é‚¢‚ÍTGAb ‚ª—z�« ‚Å‚ ‚ê‚Î�A‹´–{•a‚Æ�f’f‚µ‚Ä‚¢‚é�BTPOAb ‚ ‚é‚¢‚ÍTGAb —z�«ŽÒ‚Ì1 Š„‚ª�b�ó‘B‹@”\’ቺ�Ç ‚ɂȂé4�j�B
�R�b�ó‘B�R‘̂ɂÍTPOAb�ATGAb ‚Ì‘¼‚É TSH Žó—e‘Ì�R‘Ì�iTRAb�j‚ª‚ ‚é�BTRAb ‚É ‚Í�b�ó‘BŽhŒƒ�R‘ÌTSAb�ithyroid stimulating antibody�j‚ƃuƒ�ƒbƒLƒ“ƒO�R‘ÌTSBAb �iTSH-stimulation blocking antibody�j‚ª‚ ‚é�BŽhŒƒ�R‘ÌTSAb ‚̓oƒZƒhƒE•a‚ÌŒ´ˆö‚É‚È ‚é�Bƒuƒ�ƒbƒLƒ“ƒO�R‘ÌTSBAb ‚Í�b�ó‘B‹@”\’á ‰º�ǂ̌´ˆö‚ɂȂé�B�b�ó‘B‹@”\’ቺ�ǂ̌´ˆö‚É ‚ÍTSBAb ‚ª‚ ‚é�B
Ž©ŒÈ–Ɖu�«–��«�b�ó‘B‰Š[ a u t o i m m u n e chronic thyroiditis] [‹´–{•a�i�L‹`�j]‚É‚Í�b �ó‘BŽî‚Ì‚ ‚é‚à‚̂ƂȂ¢‚à‚Ì‚ª‚ ‚é�B‘OŽÒ�b�ó ‘BŽî‚Ì‚ ‚é‚à‚Ì‚ð‹´–{•a�i‹·‹`�j[autoimmune goitrous �iHashimoto's�j thyroiditis]‚Æ‚¢‚¢�A ŒãŽÒ�b�ó‘BŽî‚̂Ȃ¢‚à‚Ì‚ðˆÞ�k�«�b�ó‘B‰Š [autoimmune atrophic thyroiditis]‚Æ‚¢‚¤5�j�B ‚±‚̈Þ�k�«�b�ó‘B‰Š‚ł̓uƒ�ƒbƒLƒ“ƒO�R‘Ì TSBAb ‚ª—z�«‚ɂȂé�BTSBAb ‚ÍTSH Žó—e‘Ì �R‘ÌTRAb ‚Å‚ ‚é�B
‹´–{•a‚ł͎©ŒÈ–Ɖu‚É‚æ‚è�b�ó‘B‘g�D”j‰ó‚ª �¶‚¶�A�b�ó‘Bƒzƒ‹ƒ‚ƒ“‚ªŒŒ’†‚É—¬�o‚·‚邱‚Æ‚ª ‚ ‚é�B�b�ó‘B’†“Å�Ç‚ðŽ¦‚·�B‚±‚ê‚ð”j‰ó�«�b�ó ‘B‰Š‚Æ‚¢‚¤�B‚₪‚Ä‹@”\’ቺ�ǂɂȂé�B
ˆâ“`“I‘fˆö‚ª�d—v‚È–ðŠ„‚ð‰Ê‚½‚·�B‘fˆö‚Ì‚ ‚é�l‚ÉŽ©ŒÈ–ƉuˆÙ�킪‚¨‚±‚è�A‹´–{•a‚ɂȂé�B —Uˆö‚ª‚ ‚é�B
1�D‹´–{•a”�ǂ̈â“`”wŒi
‹´–{•a‚͉Ƒ°“à‚Å”�Ç‚·‚é�Bˆâ“`“I”wŒi‚ª‚ ‚é�B‹´–{•a‚Í‘¼‚ÌŽ©ŒÈ–Ɖu�«“à•ª”åŽ¾Š³‚Æ�‡•¹ ‚·‚é�BIDDM�A‹´–{•a�AƒoƒZƒhƒE•a�AAddison �iƒAƒfƒBƒ\ƒ“�j•a‚Ȃǂ̎©ŒÈ–Ɖu޾г‚Í�‡•¹‚· ‚é�B‚ ‚éŽí‚̈â“`”wŒi‚ðŽ�‚гŽÒ‚Í‹´–{•a‚Éœë ‚è‚â‚·‚¢�BHLA�ACTLA-4 ‚̈â“`Žq‘½Œ^‚ªŠÖ ŒW‚·‚é�B
2�DŽ©ŒÈ–ƉuˆÙ�í
1�j‘̉t�«–Ɖu�F�b�ó‘BŽ©ŒÈ�R‘Ì�ithyroid autoantibody�j
�@�b�ó‘B�R‘̂ɂÍT P O A b �AT G A b �A TRAb ‚ª‚ ‚é�BˆÞ�k�«�b�ó‘B‰Š‚ł̓uƒ�ƒb ƒLƒ“ƒO�R‘ÌT S B A b ‚ª—z�«‚ɂȂé�B TSBAb ‚Í�b�ó‘B‹@”\’ቺ�ǂ̌´ˆö‚Å‚ ‚é�BTSBAb ‚ÍTRAb ‚Å‚ ‚é�BTSAb ‚̓o ƒZƒhƒE•a‚ÌŒ´ˆö‚Å‚ ‚é�BTSBAb ‚àTSAb ‚àTRAb ‚Å‚ ‚é�B
2�j�×–E�«–Ɖu�icell-mediated immunity�j
�@�×–E�«–Ɖu‚Í�R‘Ì‚ªŠÖ—^‚µ‚È‚¢‚Å�A�×–E ‚ª’¼�Ú�ì—p‚·‚é–Æ‰u”½‰ž‚Å‚ ‚é�B�b�ó‘B‚É ‘΂·‚é�×–E�«–Ɖu‚ª‚ ‚é�B�b�ó‘B‚É‚ÍƒŠƒ“ ƒp‹…‚Ì�Z��‚ª‚ ‚è�A‚±‚ÌƒŠƒ“ƒp‹…‚Í�b�ó‘B �×–E‚É’¼�Ú�ì—p‚·‚é�B
3�j�R‘̈ˑ¶�«�×–E�«�×–E��ŠQ�iantibodydependent cellular cytotoxicity �F ADCC�j
�@‰t�«�R‘Ì‚Æ�×–E�«–Ɖu‚Ì‹¦“¯�ì—p‚Æ‚µ‚Ä ADCC ‚ª‚ ‚é�BADCC ‚Í‹´–{•a‚Å‚à‚Ý‚ç ‚ê‚é�B–Ɖu�×–E‚Í�R‘Ì‚ð’‡‰î‚Æ‚µ�A•W“I�× –E‚É•t’…‚µ�A�×–E‚É��ŠQ‚ð—^‚¦‚é�B‚±‚Ì‚æ ‚¤‚È�ì—p‚ðŽ¦‚·–Ɖu�×–E‚ÍK �×–E�iƒLƒ‰�[ T �×–E�j‚Å‚ ‚é�B�R‘ÌŽ©�g‚Í�b�ó‘B�×–E‚ð ��ŠQ‚µ‚È‚¢�B�R‘Ì‚Í�×–E•\–ʂɌ‹�‡‚µ�A–Æ ‰u•¡�‡‘Ì‚ª‚Å‚«‚é�B‚±‚̖Ɖu•¡�‡‘Ì‚Ì�R‘Ì Fc •”•ª‚ÉK �×–E‚ªŒ‹�‡‚µ�A�b�ó‘B�×–E“à ‚É“ü‚Á‚Ä�×–E‚ð”j‰ó‚·‚é�BADCC ‚͈Þ�k �«�b�ó‘B‰Š�A‹´–{•a‚ł݂ç‚ê‚é�B
‹´–{•a�AƒoƒZƒhƒE•a”�ǂɂ̓wƒ‹ƒp�[T �×–E �iTH �×–E�j‚ª�d—v‚È–ðŠ„‚ð‰Ê‚½‚·�B‹´–{•a‚Å ‚ÍTH1 —DˆÊ�AƒoƒZƒhƒE•a‚Å‚ÍTH2 —DˆÊ‚Å‚ ‚é�B ‹´–{•a‚Å‚Í�×–E�áŠQ”½‰ž�AƒoƒZƒhƒE•a‚Å‚Í�R‘Ì TRAb�iTSAb�jŽY�¶‚ªŽå‘̂ɂȂé�B‚µ‚©‚µ�A ƒuƒ�ƒbƒLƒ“ƒO�R‘ÌTSBAb —z�«ˆÞ�k�«�b�ó‘B‰Š ‚Å‚ÍTH2 —DˆÊ‚Å‚ ‚é�B�R‘ÌTRAb�iTSBAb�j ŽY�¶�iTH2�j‚ªŽå‘̂ɂȂ邪�A�×–E�áŠQ�iTH1�j ‚à‚Ý‚ç‚ê‚é�B
3�D‹´–{•a”�Ç�E‘�ˆ«‚̊‹«ˆöŽq2,3�j
ƒˆ�[ƒh‚Í‹´–{•a‚Ì”�Ç�A‘�ˆ«‚ÉŠÖŒW‚·‚é�Bƒˆ �[ƒhŒ‡–R’nˆæ‚Å‚Í�—ʃˆ�[ƒh“Š—^‚ª‹´–{•a‚Ì” �Ç•p“x‚ð—}‚¦‚é�Bˆê•û�A‘å—ʃˆ�[ƒh‚Í‹´–{•a‚Ì ”�Ç‚â‘�ˆ«‚ÉŠÖ—^‚·‚é�BAmiodarone ‚̓ˆ�[ƒh‚ð ŠÜ—L‚µ‚Ä‚¨‚è�A�b�ó‘BŽ©ŒÈ–Ɖu޾г‚ð—U”‚·‚é�B
ƒoƒZƒhƒE•aгŽÒ‚ðI131 •úŽË�ü‚ÅŽ¡—·‚邯�A ƒuƒ�ƒbƒLƒ“ƒO�R‘Ì�iTSBAb�j‚ª�oŒ»‚µ�A�b�ó ‘B‹@”\’ቺ�ǂɂȂé—Ⴊ‚ ‚é�BI131 •úŽË�üŽ¡—à ŒãTRAb ‚ª�‚’l‚ɂȂé—Ⴊ‚ ‚é�B‚±‚ê‚ÍI131 ‚Å �b�ó‘B‚ª”j‰ó‚³‚ê�AŒŒ’†‚É�b�ó‘B‘g�D‚ª—¬�o ‚µ�A‚»‚Ì—¬�o‚µ‚½�b�ó‘B‘g�D‚ª�RŒ´‚ƂȂÁ‚Ä�R‘Ì‚ð�ì‚é�BI131 •úŽË�ü—Ö@‚ªŽ©ŒÈ–Ɖu�«�b�ó‘B ‰Š‚ðˆø‚«‹N‚±‚·�B‚Ü‚½ˆŸ‹}�«�b�ó‘B‰Š‚ÌŒã‚É TSBAb ‚ª�o‚Ä‚«‚Ä‹@”\’ቺ�ǂɂȂé—Ⴊ‚ ‚é�B
ƒCƒ“ƒ^�[ƒtƒFƒ�ƒ“Ž¡—Âɂæ‚è�A–��«�b�ó‘B‰Š ‚ª‘�ˆ«‚ ‚é‚¢‚Í”�Ç‚·‚é�B
”D�P�E�oŽY‚ÉŠÖ˜A‚µ‚½Ž©ŒÈ–Ɖu�«�b�ó‘B‹@”\ ˆÙ�í�Ç‚ª‚ ‚é�BCushing�iƒNƒbƒVƒ“ƒO�j�pŒã‚ ‚é‚¢‚Í•›�t”玿ƒzƒ‹ƒ‚ƒ““Š—^’†Ž~Œã�b�ó‘B‹@”\ ˆÙ�í�Ç‚ª‹N‚±‚é�B�u‰ß�è•›�t”玿ƒzƒ‹ƒ‚ƒ“‚ª‹}Œƒ ‚ɒቺ‚µ‚½‚Æ‚«‚É�b�ó‘B‹@”\ˆÙ�í�Ç‚ª�o‚Ä‚‚é�v ‚Æ‚¢‚¤‚±‚Æ‚Í�oŽYŒã‚Ì�b�ó‘B‹@”\ˆÙ�í�ǂ̔�Ç ‹@�˜‚ð�à–¾‚·‚é�BƒXƒeƒ�ƒCƒh‚Ì‹}Œƒ‚ȕω»‚ªŽ© ŒÈ–ƉuˆÙ�í�A�b�ó‘B‹@”\ˆÙ�í‚ðˆø‚«‹N‚±‚·�B
Human T-lymphotrophic virus type I �iHTLV-I�jŠ´�õŽÒ‚ł͎©ŒÈ–Ɖu޾г‚ª‘½‚¢�B ‹´–{•a‚Ì•p“x‚à‘½‚¢4�j�Bƒ`ƒGƒ‹ƒmƒuƒCƒŠ•úŽË�ü Ž–ŒÌ‚Å–��«�b�ó‘B‰Š‚ª‘�‰Á‚µ‚½�B
�—�«‚É‘½‚¢�B’j�«1 ‚ɑ΂µ�—�«2 �` 7 ‚Å‚ ‚é�B 30 �` 60 �Αä‚É‘½‚¢�B�R�b�ó‘B�R‘Ì‚ª—z�«‚É‚È ‚é‚Ì‚Í�¬�l�—�«‚Ì10 �` 20 �“‚Å‚ ‚é�B�b�ó‘B�R ‘Ì—z�«ŽÒ‚Ì10 �“‚ª�b�ó‘B‹@”\’ቺ�ǂɂȂé4�j�B �¬�l‚Ì‹´–{•a‚É‚æ‚é�b�ó‘B‹@”\’ቺ�ǂ̕p“x‚Í ‚Ù‚ÚƒoƒZƒhƒE•a‚Ì•p“x‚Æ“¯‚¶‚Å‚ ‚é�B
�b�ó‘B‚͂т܂ñ�«‚ÉŽî‘債�A•\–ʂ͑e‘åè÷—± �ó‚Å�d‚¢�B‘g�DŠw“I‚É‚Í1�j�‚“xƒŠƒ“ƒp‹…�Z���A ƒŠƒ“ƒpàh–E�Eãó’†�S‚ÌŒ`�¬�A2�jŠÔŽ¿‘@ˆÛ‰»�A‘@ ˆÛ‘��B�A‚»‚µ‚Ä3�jàh–E�ã”ç�×–E•Ï�«�AˆÈ�ã3 ‚ ‚ª‹´–{•a�b�ó‘B‚Ì“Á’¥‚Å‚ ‚é1�j�B•a•Ï‚ª�b�ó‘B ‘S‘̂ɋy‚ñ‚Å‚¢‚é‚à‚Ì�i‚т܂ñ�«�b�ó‘B‰Šdiffuse thyroiditis�j�A•a•Ï‚ªŽU�Ý‚·‚é‚à‚Ì�iŽU�Ý �«�b�ó‘B‰Šfocal thyroiditis�j�A‚»‚µ‚ÄƒŠƒ“ƒp ‹…�Z��‚ðŽU�Ý�«‚É”F‚߂邾‚¯‚Ì‚à‚Ì‚à‚ ‚é�B
�b�ó‘BŽî‚ª‚ ‚é�B�b�ó‘BŽî‚͂т܂ñ�«‚Å�A�Å �‰‚Í�_‚ç‚©‚¢‚ª�A‚₪‚Ä�d‚‚È‚é�B•\–ʂ͕s �®�BŽ©”’É�Aˆ³’ɂ͂Ȃ¢�BŒz•”ˆá˜aŠ´�E•s‰õŠ´‚ð‘i‚¦‚é�B�b�ó‘B‹@”\‚Í�‰‚ß‚Í�³�í‚Å‚ ‚邪�A ‚₪‚Ä�b�ó‘B‘g�D‚ª”j‰ó‚³‚ê�A�b�ó‘B‹@”\’ቺ �ǂɂȂé�B�‰Šú‚Å‚Í�b�ó‘BŽî‚݂̂ð”F‚ß‚é�B
�b�ó‘B‹@”\’ቺ�ǂɂȂé�B�b�ó‘B‹@”\’ቺ�Ç ‚Í“Á—L‚ÌŠç–e�A�º�A˜b‚µ•û‚©‚ç�f’f‚·‚é�B‚Ü‚½ ‚»‚Ì“Á’¥“I‚È�º‚©‚ç“d˜b‚Å‚à�f’f‚Å‚«‚é�B�‰Šú ‚Ì�Ç�ó‚Í”ñ“ÁˆÙ“I‚Å�A‘½�ʂł ‚é�B�b�ó‘Bƒzƒ‹ ƒ‚ƒ“Œ‡–R‚É‚æ‚è�A‘ãŽÓ‚ª’ቺ‚µ�Aƒ€ƒR‘½“œ—Þ‚ª ’¾’…‚µ�A”S‰t�…Žî‚ª‚Ý‚ç‚ê‚é�B—Õ�°�Ç�ó‚Í2 ‚ ‚É•ª‚¯‚邱‚Æ‚ª‚Å‚«‚é�i•\1�j�B1�j�b�ó‘Bƒzƒ‹ƒ‚ ƒ“Œ‡–R‚É‚æ‚é�V’‘ãŽÓ’ቺ‚Ì�Ç�ó‚Æ2�j”S‰t�…Žî �«�Z��‚É‚æ‚é�Ç�ó‚Å‚ ‚é�B”S‰t�…Žî�«�Z��‚̓q ƒAƒ‹ƒ�ƒ“Ž_‚âƒRƒ“ƒhƒ�ƒCƒ`ƒ“—°Ž_‚É•x‚Þƒ€ƒR’` ”’‚Ì‘g�DŠÔŒ„‚Ö‚Ì’¾’…‚É‚æ‚é•‚Žî‚Å‚ ‚è�Aˆ³� ‚ðŽc‚³‚È‚¢non-pitting edema ‚Å‚ ‚é�B
•a—ð�A–â�f‚Å“¾‚ç‚ê‚é�d—v‚È�ŠŒ©‚Í�º‚̕ω» ‚Å‚ ‚é�B�b�ó‘Bƒzƒ‹ƒ‚ƒ“‚ªŒ‡–R‚·‚邯�º‘тɕ‚ Žî‚ª�¶‚¶šm‚ê�º‚ɂȂé�B�ã‚̉^“®‚ªˆ«‚�A‰ï˜b ‚ª‚̂낂Ȃè�A“ï’®‚à�¶‚¶‚é�B‰ï˜b‚ª“‚‚È ‚é�B�u–°‚¢�v�A�uЦ‚³‚ÉŽã‚¢�v�A�u‹L‰¯—͒ቺ�v�A �u•Ö”é�v‚Ȃǂ𕷂«�o‚·�B‚±‚ê‚ç‚Í�b�ó‘Bƒzƒ‹ƒ‚ƒ“Œ‡–R‚ª’·ŠúŠÔ‘±‚¢‚½‚±‚Æ‚ðŽ¦‚·�BäC• ‹Ø‚Ì áz�¹�i‚±‚Þ‚ç•Ô‚è�j‚Í‘�Šú‚É�oŒ»‚·‚é�B
Ž‹�f‚Å‚Í�A”畆‚ª�b�ó‘Bƒzƒ‹ƒ‚ƒ“Œ‡–R‚É•qŠ´ ‚É”½‰ž‚·‚é�BŒ‡–R‚·‚邯�A”畆‚ÍŠ£‘‡‚µ�A‘e ‚ɂȂé�B”畆‚Å�b�ó‘B‹@”\’ቺ�Ç‚ð‹^‚¤�B”S‰t �…Žî—lŠç–e‚Í“Á’¥“I�B“ª”¯‚Ì’E–Ñ�A”û–ÑŠO‘¤ 1/3 ‚Ì’E—Ž�A–³‹C—Í—lŠç–e‚ªŒ©‚ç‚ê‚é�B�b�ó‘B Žî‚ª‚ ‚é�B”畆‚Ì�F‘f’¾’…‚ÍSchmidt�iƒVƒ…ƒ~ ƒbƒg�j�ÇŒóŒQ‚ðަ�´‚·‚é�BSchmidt �ÇŒóŒQ‚Í‹´ –{•a‚ÆAddison •a‚Ì�‡•¹�B
Ž©Šo�Ç�ó‚Æ‚µ‚Ä‚Í�A•‚Žî�i•‚ŽîŠ´�j�AЦ‚ª‚è�A ˆÕ”æ˜JŠ´�Ašm‚ê�º�AŒ¾—t‚Ì‚à‚‚ê�A“®�ìŠÉ–��A �¸�_“Ý–ƒ�A–°‚ª‚è�A“ï’®�A”ç•†Š£‘‡�i”§�r‚ê�j�A ’E–Ñ�A‘Ì�d‘�‰Á�AŒŽŒo‰ß‘½‚Ȃǂª‚é�B‘¼Šo“I‚É ‚Í�A”S‰t�…Žî—lŠç–e�AŒû�O‚â�ã‚ÍŒú‚�i‹�‘å �ã�j�A’E–Ñ‚ª‚ ‚è�A”û–Ñ‚àŠO‘¤1/3 ‚ª”–‚¢�B”ç •†‚ÍŠ£‘‡‚µ�A‘e?‚Å‚ ‚è�A‰©�F�iƒJƒ�ƒ`ƒ“ŒŒ �Ç�j‚ɂȂé�BŽè‘«‚É•‚Žî‚ª‚ ‚è�Aˆ³�‚ðŽc‚³‚È ‚¢�B�º‚Í’á‚�Ašm‚ê�º‚ɂȂé�BŒ¾Œê�A“®�ì‚ÍŠÉ –�‚Å‚ ‚é�B�b�ó‘BŽî‚ª‚ ‚ê‚Î�f’f‚Í—eˆÕ‚Å‚ ‚é ‚ª�A�b�ó‘BŽî‚̂Ȃ¢‚à‚Ì‚à‚ ‚é�B�S‘Ÿ‚ÍŠg‘債�A �S‰¹‚Í”÷Žã�A�™–¬‚ɂȂé�BŽž‚ɂ͋¹�…‚â• �…‚ð ‚Ý‚é�BƒAƒLƒŒƒXäF”½ŽË‚Ì’oŠÉ‘Љ„’·‚Í�f’f“I‰¿ ’l‚ª‚ ‚é�B
•\1
�b�ó‘BŽ©ŒÈ�R‘Ì�iTPOAb�ATGAb�j‚ª—z�« ‚ɂȂé�B�b�ó‘B‹@”\‚ÍŒŒ’†�b�ó‘Bƒzƒ‹ƒ‚ƒ“�iT 3�AT4�A—V—£T3�A—V—£T4�j‚ÆŒŒ’†TSH ‚Å‚Ý ‚é�BTSH ‚ÌŠî�€’l‚Í0.4 �` 4.0 ƒÊ U/ml�imU/l�j ‚Å‚ ‚é�B‹´–{•a‚Í�b�ó‘B�«‚Ì�b�ó‘B‹@”\’ቺ�Ç ‚Å‚ ‚è�ATSH ‚ª�‚’l‚ƂȂé�BTSH 10 ƒÊ U/ml ˆÈ�ã‚ÌŠ³ŽÒ‚Í‹´–{•a‚Ì10 �“‚Å‚ ‚é�B‹´–{•a‚Å ‚Í�b�ó‘B‘g�D‚ª”j‰ó‚³‚ê�A�b�ó‘Bƒzƒ‹ƒ‚ƒ“‚ªŒŒ ’†‚ɘR�o‚·‚邽‚ß�Aˆê‰ß�«‚É�b�ó‘B’†“Å�Ç‚É‚È ‚é�B‚»‚ÌŽž�AŒŒ’†TSH ‚Í’á’l‚ðŽ¦‚·�B
ˆê”ÊŒŸ�¸‚Å‚Í�AŒŒ’¾‚ª˜´�i‚µ�AƒÁ-ƒOƒ�ƒuƒŠ ƒ“‚ª‘�‰Á‚·‚é�BCPK ‚âLDH ‚ª‘�‰Á‚·‚é�BŒŒ’† chol ‚Í�‚’l�B‹¹•”X �üŽÊ�^‚Å�SŠg‘å�A�S“d�} ‚Å‚Í�™–¬�A’á“dˆÊ�AT ‚Ì•½’á�E‰A�«‰»‚ª‚Ý‚ç‚ê ‚é�B�b�ó‘B’´‰¹”g‚Å‚Í�b�ó‘BŽî‘傯‘e?‰»‚ð ‚Ý‚é�BŒŒ’†ƒvƒ�ƒ‰ƒNƒ`ƒ“‚ª�‚’l‚ɂȂé�B‰º�‚‘Ì ‚ª‘å‚«‚‚È‚é�B
�b�ó‘BŽ©ŒÈ�R‘Ì�iTPOAb�ATGAb�j‚Í—z�«‚É ‚È‚é�B�b�ó‘BŽî‚ª‚ ‚è�A�b�ó‘B�R‘Ì‚ª—z�«‚Å‚ ‚邯‚«‹´–{•a‚ð�l‚¦‚é�BTRAb ‚ª—z�«‚ɂȂ邱 ‚Æ‚ª‚ ‚é�B‚±‚ÌTRAb ‚ÍTSBAb ‚Å‚ ‚é�B�b�ó ‘B‹@”\’ቺ�Ç‚Ì�f’f‚Í�b�ó‘B‹@”\ŒŸ�¸‚É‚æ‚é�B ŒŒ’†�b�ó‘Bƒzƒ‹ƒ‚ƒ“‚Í’á’l‚ðŽ¦‚·�B‹´–{•a‚Ì‚æ ‚¤‚È�b�ó‘B�«�b�ó‘B‹@”\’ቺ�ǂłÍ�ATSH ‚ª�‚ ’l‚ƂȂé�BTSH ‚ÌŠî�€’l‚Í0.4 �` 4.0 ƒÊ U/ml ‚Å ‚ ‚é�B—Õ�°�Ç�ó‚ª�o‚Ä‚¢‚È‚¢—á‚Å‚à�ATSH ‚Í�‚ ’l‚ƂȂè�A‘�Šú�f’f‚É–ð—§‚Â�B—V—£T3�A—V—£ T4 ‚ª�³�í‚Å�ATSH ‚ª4.0 �` 10 ƒÊ U/ml ‚Ì‚à‚Ì ‚ð�ö�Ý�«�b�ó‘B‹@”\’ቺ�ǂƂ¢‚¤�B
�b�ó‘Bƒzƒ‹ƒ‚ƒ“‚𓊗^‚·‚é�B•â�[—Ö@‚Å‚ ‚é�BT4 ‚Å•â�[‚·‚é�BTSH 10 ƒÊ U/ml ˆÈ�ã‚Ì Š³ŽÒ‚ÍT4 ‚ð•â�[‚·‚é�BT4 “Š—^‚Í�‚—îŽÒ‚Å‚Í �S‹Ø�[�Ç�A‹·�S�Ç‚ð—U”‚·‚é�B‰º�‚‘Ì�«�b�ó ‘B‹@”\’ቺ�ǂł͂Ƃ«‚ɉº�‚‘Ì�«•›�t”玿‹@ ”\’ቺ�Ç‚ð�‡•¹‚·‚é�B‚±‚̂悤‚È—á‚ÅT4 ‚𓊠—^‚·‚邯•›�t•s‘S‚ðˆø‚«‹N‚±‚·�BT4 “Š—^‘O‚É •›�t”玿ƒzƒ‹ƒ‚ƒ“‚𓊗^‚·‚é�BSchmidt �ÇŒóŒQ ‚Å‚à“¯‚¶‚悤‚ÉT4 “Š—^‘O‚É•›�t”玿ƒzƒ‹ƒ‚ƒ“ ‚𓊗^‚·‚é�BT4 •â�[‚ÅTSH ‚ð�³�í‚ɕۂ‚悤 ‚É‚·‚é�B
1�j�b�ó‘B‹@”\’ቺ�Ç6�j
�b�ó‘B‹@”\’ቺ�ǂ͇T. �b�ó‘B�«�iŒ´”�«�j�A ‡U. Ž‹�°‰º•”�«�A‰º�‚‘Ì�«�i“ñŽŸ�«�j�A‡V.––�½ �«�b�ó‘B‹@”\’ቺ�Ç‚Ì3 ‚‚ɕª—Þ‚·‚é�i•\2�j�B ‡V‚Í�b�ó‘Bƒzƒ‹ƒ‚ƒ“•s‰ž�ǂł ‚é�B‡T‚Ì�b�ó‘B �«�iŒ´”�«�j�b�ó‘B‹@”\’ቺ�ǂɂ͂¢‚ë‚¢‚ë‚ ‚邪�AŽ©ŒÈ–Ɖu‚É‚æ‚é–��«�b�ó‘B‰Š‚ª‘½‚¢�BŒŒ ’†�b�ó‘Bƒzƒ‹ƒ‚ƒ“‚Ɖº�‚‘ÌTSH •ª”傯‚ÌŠÔ‚É ‚Ínegative feedback ‚ª‚ ‚è�A�b�ó‘B�«�b�ó‘B ‹@”\’ቺ�ǂł͌Œ’†TSH ‚ª‘�‰Á‚·‚é�B
–��«�b�ó‘B‰Š‚É‚Í�b�ó‘BŽî‚Ì‚ ‚é–��«�b�ó‘B ‰Š�i‹´–{•a�j‚Æ�b�ó‘B‚ð�G‚ê‚È‚¢ˆÞ�k�«�b�ó‘B ‰Š‚Æ‚ª‚ ‚é�BˆÞ�k�«�b�ó‘B‰Š‚ł̓uƒ�ƒbƒLƒ“ƒO �R‘ÌTSBAb ‚ª—z�«‚ɂȂé�BTSBAb ‚ÍTRAb ‚Å‚ ‚é�Bƒuƒ�ƒbƒLƒ“ƒO�R‘ÌTSBAb ‚Í�b�ó‘B‹@ ”\‚ð—}�§‚µ�A�b�ó‘B‹@”\’ቺ�ǂ̌´ˆö‚ɂȂé5�j�B TSBAb ‚ÍTSH ‚Ì�ì—p‚ðƒuƒ�ƒbƒN‚µ�A�b�ó‘B ‹@”\‚ð—}�§‚·‚é�B
•\2
�}1�D‹´–{•a�i‘g�D‚Å�f’f�j‚Æ�R‘ÌTGAb A ‚ÆTPOAb B ‚ÌROC ‰ð�Í2�j
2�jTPOAb�ATGAb�ATSBAb ‚Æ�b�ó‘B‹@”\’á ‰º�Ç
‹´–{•a‚Ì�f’f‚Í‘g�D�f‚Å‚ ‚邪�A‘S‚Ä‚Ì�Ç—á ‚Å‘g�D‚ð‚݂邱‚Ƃ͂ł«‚È‚¢�B�]‚Á‚ÄTPOAb�A TGAb ‚ª—z�«‚Å�A�b�ó‘B‹@”\’ቺ�Ç‚ª‚ ‚邯 ‚«�A‹´–{•a‚É‚æ‚é�b�ó‘B‹@”\’ቺ�Ç‚ð�l‚¦‚é�B
T P O A b�AT G A b ‚̓oƒZƒhƒE•a‚ÌT R A b �iTBII �ETSAb�j‚Ù‚ÇŠ´“x�E“ÁˆÙ“x‚ª—Ç‚‚Í‚È ‚¢�i�}1�j2�j�B‹´–{•a‚Å‚Í�b�ó ‘Bàh–E‚ª”j‰ó‚³‚ê�AŒŒ’†‚É�b�ó ‘Bƒyƒ‹ƒIƒLƒVƒ_�[ƒ[�iTPO�j ‚ƃTƒCƒ�ƒOƒ�ƒuƒŠƒ“�iTG�j‚ª —¬�o‚µ‚Ä�RŒ´‚ƂȂè�A�R‘Ì TPOAb ‚ÆTGAb ‚ª‚Å‚«‚é�B�b �ó‘B‹@”\’ቺ�ǂ͋´–{•a‚É‚æ ‚è�b�ó‘B‚ª”j‰ó‚³‚ꂽŒ‹‰Ê‚Å‚ ‚é�BTPOAb�ATGAb ’l‚Æ�A�b �ó‘B‹@”\’ቺ�ǂ̒ö“x‚ª‘ŠŠÖ ‚·‚邯‚ÍŒÀ‚ç‚È‚¢�BTPOAb ‚Æ TGAb ‚Í�b�ó‘B‹@”\’ቺ�Ç‚Ì Œ´ˆö‚ł͂Ȃ¢�B
TPOAb�ATGAb ‚Í�b�ó‘B‹@ ”\’ቺ�ǂ̌´ˆö‚ł͂Ȃ¢�B‚»‚Ì —�—R‚Í1�jTPOAb �ETGAb ‚Æ ‚à‘ª’芴“xˆÈ‰º‚Å‚ ‚é‚É‚à‚©‚© ‚í‚炸�A‹´–{•a‚Ì‘g�D•ω»‚Æ�b �ó‘B‹@”\’ቺ�Ç‚ðŽ¦‚·�ǗႪ‚ ‚é�B‚±‚Ì‚±‚Æ‚ÍTPOAb �E TGAb ‚Í‹´–{•a�E�b�ó‘B‹@”\ ’ቺ�ǂ̕aˆö‚łȂ¢‚±‚Æ‚ðަ�´ ‚µ‚Ä‚¢‚é�B2�jTPOAb �ETGAb ‚Í‹´–{•a‚Å—z�«‚ɂȂ邪�A TPOAb �ETGAb ‚Í�b�ó‘B‹@”\ ‚ð—}�§‚·‚é‚킯‚ł͂Ȃ¢�B
TPOAb �ETGAb ‚Í‹´–{•a‚Ì Žw•W‚É‚·‚¬‚È‚¢�B
ƒuƒ�ƒbƒLƒ“ƒO�R‘ÌTABAb ‚Í �b�ó‘B‹@”\’ቺ�ǂ̌´ˆö‚Å‚ ‚é5,7,8,16�j�B‚»‚Ì—�—R‚͇@ƒuƒ�ƒb ƒLƒ“ƒO�R‘ÌTSBAb ‚Í�b�ó‘B‹@ ”\’ቺ�Ç‚ðˆø‚«‹N‚±‚·5,7,8,16�j�B TSBAb ‚͈Þ�k�«�b�ó‘B‰Š‚ÌŒ´ ˆö‚ɂȂé�BTSBAb ‚Í�b�ó‘B‚ð ˆÞ�k‚³‚¹‚é�B2�j TSBAb ’l‚Æ—Õ �°Œo‰ß‚ªˆê’v‚·‚é8�j�BTSBAb ‚ª �Áޏ‚·‚邯�b�ó‘B‹@”\’ቺ�Ç‚© ‚ç‰ñ•œ‚·‚é8�j�B3�j TSBAb ‚Í�V�¶ Ž™ˆê‰ß�«�b�ó‘B‹@”\’ቺ�ǂ̌´ ˆö‚ɂȂé7�j�BTSBAb ‹—z�«‚Ì•ê �e‚ÌTSBAb ‚͑ٔՂð’ʉ߂µ�A Ž™‚ɈÚ�s‚·‚é�B‚±‚ÌTSBAb ‚ª Ž™‚Ì�b�ó‘B‚ð—}�§�A�b�ó‘B‹@”\ ’ቺ�Ç‚ðˆø‚«‹N‚±‚·�B
TABAb ‚Í�b�ó‘B‹@”\’ቺ�Ç ‚ÌŒ´ˆö‚Å‚ ‚é�B
3�j�b�ó‘B‹@”\’ቺ�Ç‚©‚ç‰ñ•œ ‚·‚é‚à‚Ì9�j
�¬�l‚Ì�b�ó‘B‹@”\’ቺ�Ç‚Ì‘å •”•ª‚Í–��«�b�ó‘B‰Š‚É‚æ‚é�B–� �«�b�ó‘B‰Š‚É‚æ‚é‹@”\’ቺ�Ç‚Í ‰i‘±‚·‚é‚à‚Ì‚Æ�l‚¦‚ç‚ê‚Ä‚« ‚½�B‘å•”•ª‚Í�b�ó‘Bƒzƒ‹ƒ‚ƒ“•ž —p‚𒆎~‚Å‚«‚È‚¢�b�ó‘B‹@”\’á ‰º�ǂł ‚é�B‚µ‚©‚µ’†‚É‚Í�b�ó ‘Bƒzƒ‹ƒ‚ƒ“•ž—p‚𒆎~‚Å‚«‚銳 ŽÒ‚ª‚¢‚é10�j�B’†Ž~‚Å‚«‚é‚à‚Ì �i‰Â‹t�«�b�ó‘B‹@”\’ቺ�Ç�j‚É ‚ÍŽŸ‚Ì‚à‚Ì‚ª‚ ‚é�B
1�j‰ß�胈�[ƒh“Š—^�E�ÛŽæ‚É ‚æ‚é�b�ó‘B‹@”\’ቺ�Ç‚Í ƒˆ�[ƒh�§ŒÀ‚ʼnñ•œ
�@‰ß�胈�[ƒh�ÛŽæ‚É‚æ‚è�b�ó ‘B‹@”\’ቺ�ǂɂȂ邱‚Æ‚ª‚ ‚é�i�}2�j�Bƒˆ�[ƒh�§ŒÀ‚É‚æ ‚è�b�ó‘B‹@”\’ቺ�Ç‚©‚ç‰ñ•œ ‚·‚é�Bƒˆ�[ƒh‘¢‰e�܂ɂæ‚è�b �ó‘B‹@”\’ቺ�ǂɂȂé—Ⴊ‚ ‚é�BAmiodarone‚Í1 �ù�i100mg�j‚É37.3mg‚̃ˆ�[ƒh‚ðŠÜ‚Þ�B Amiodarone ‚Í�b�ó‘B‹@”\’ቺ�ǂ̌´ˆö‚É‚È ‚é�BŠî‘b‚É‹´–{•a‚ª‚ ‚é�B
�}2�D‹´–{•a‚ÌŠ³ŽÒ‚Ńˆ�[ƒh‘¢‰e�܂ɂæ‚è�b�ó‘B‹@”\’ቺ�ǂɂȂÁ‚½—á
75�Î�—�«�B�b�ó‘B‹@”\�³�í‚Ì‹´–{•a‚ÅŒo‰ß‚ðŠÏ‚Ä‚¢‚½�B�®Œ`ŠO‰È‚Ńˆ�[ƒh‘¢‰e�Ü
‚ð�Ã’�Œã�A�b�ó‘B‹@”\’ቺ�ǂɂȂÁ‚½�B‚»‚ÌŒã�b�ó‘B‹@”\’ቺ�Ç‚©‚ç‰ñ•œ‚µ‚½9�j�B
�}3. Rifampicin�iRFP�j‚É‚æ‚é�b�ó‘B‹@”\’ቺ�Ç11�A12�j
62 �Ë’j�«�B”xŒ‹ŠjŽ¡—ÂÉRifampicin ‚𓊗^‚µ‚½�BTSH 170 mU/l ‚ɂȂÁ‚½�B
�b�ó‘B‹@”\’ቺ�ǂɂȂÁ‚½�BT4 ‚𓊗^‚µ‚½�B
T3 �F Triiodothyronine; T4 �F Thyroxine; TSH �F Thyroid-stimulating hormone
2�j–ò�܂ɂæ‚é�b�ó‘B‹@”\’ቺ�Ç
�@Rifampicin ‚Í�b�ó‘B‹@”\’ቺ�Ç‚ð—U”‚·‚é �i�}3�j11,12�j�B–��«�b�ó‘B‰Š�i‹´–{•a�j‚ÌŠ³ŽÒ‚É�RŒ‹Šj�ÜRifampicin ‚𓊗^‚·‚邯�A �b�ó‘B‹@”\’ቺ�ǂɂȂ邱‚Æ‚ª‚ ‚é�B Rifampicin‚ÍŠÌ‘Ÿ‚Å‚Ì�b�ó‘Bƒzƒ‹ƒ‚ƒ“ ‘ãŽÓ‚ð‘£�i‚·‚é�B�b�ó‘Bƒzƒ‹ƒ‚ƒ“‚Ì‘ãŽÓ ‚ª‘£�i‚³‚ê�A�b�ó‘B‹@”\’ቺ�ǂɂȂé�B Rifampicin“Š—^’†‚ÍT4‚𓊗^‚·‚é�B�b �ó‘B‹@”\’ቺ�Ç‚ð—U”‚·‚é–ò�܂͑½‚¢ �i•\3�j�B
•\3�D�b�ó‘Bƒzƒ‹ƒ‚ƒ“�‡�¬�E•ª”å�A‘ãŽÓ‚ɉe‹¿‚ð‹y‚Ú‚µ�A �b�ó‘B‹@”\’ቺ�ǂ̌´ˆö‚ɂȂé–ò�Ü

3�j–³’É�«�b�ó‘B‰Š
�@Ž©ŒÈ–Ɖu�«�b�ó‘B‰Š‚ňê‰ß�«‚Ì�b�ó‘B‘g�D ”j‰ó‚ð�¶‚¶�Aˆê‰ß�«�b�ó‘B‹@”\’ቺ�Ç‚É‚È ‚é�BŽYŒã‚ƃNƒbƒVƒ“ƒO�pŒã�b�ó‘B‹@”\’ቺ�Ç ‚Í‚±‚Ì“ÁŽêŒ^�B
4�jŽYŒãˆê‰ß�«�b�ó‘B‹@”\’ቺ�Ç
�@ŽYŒã�b�ó‘B‹@”\ˆÙ�í�Ç‚ª‚ ‚é�BŽYŒãˆê‰ß�« �b�ó‘B‹@”\’ቺ�Ç‚ª‚ ‚é�B–��«�b�ó‘B‰Š�i‹´ –{•a�j‚Å‚ ‚é�BŽYŒã�b�ó‘B‹@”\ˆÙ�í�ǂ̒†‚Å ‚àŽYŒãˆê‰ß�«�b�ó‘B‹@”\’ቺ�ǂ͕p“x‚ª‘½ ‚¢�B”D�P‚É‚æ‚èˆêŽž“I‚ɃXƒeƒ�ƒCƒh‰ß�è‚É‚È ‚è�A•ª•؂ɂæ‚èƒXƒeƒ�ƒCƒh‰ß�è‚©‚ç‰ð•ú‚³ ‚ê�A–ƉuˆÙ�킪‹N‚±‚é�BŽYŒã�b�ó‘B‹@”\ˆÙ�í �ǂ̔�Ç‹@�˜‚ðŽŸ‚ÉŽ¦‚·ƒNƒbƒVƒ“ƒO�pŒã�b�ó ‘B‹@”\ˆÙ�í�Ç‚Í�à–¾‚·‚é�B
5�jƒNƒbƒVƒ“ƒO�pŒãˆê‰ß�«�b�ó‘B‹@”\’ቺ�Ç
�@ƒNƒbƒVƒ“ƒO�pŒã�b�ó‘B‹@”\ˆÙ�í�Ç‚ª‚ ‚é13,14�j�B ƒNƒbƒVƒ“ƒO�pŒã‚Ɉê‰ß�«‚ ‚é‚¢‚͉i‘±�«‚Ì�b �ó‘B‹@”\’ቺ�ǂɂȂé‚à‚Ì‚ª‚ ‚é�i�}4�j�BƒNƒbƒVƒ“ƒO‚ŃXƒeƒ�ƒCƒh‰ß�è‚É‚È ‚è�A–Ɖu”½‰ž‚ª—}�§‚³‚ê�A‚»‚µ ‚ÄŽè�p‚É‚æ‚èƒXƒeƒ�ƒCƒh‰ß�è‚© ‚ç‰ð•ú‚³‚ê‚邯�A–ƉuˆÙ�킪‹N ‚±‚é�B
�}4�DƒNƒbƒVƒ“ƒO�pŒãˆê‰ß�«�b�ó‘B‹@”\’ቺ�Ç13,14�j
27�΂ÌCarney's complex‚Ì’j�«�B‰¡Ž²0‚̓NƒbƒVƒ“ƒO�Ç
ŒóŒQ‚ɑ΂·‚éŽè�p‚Åbilateral adrenalectomy‚ð‚µ‚½Žž‚ð•\
‚í‚·�BX‚Í•›�t”玿ƒzƒ‹ƒ‚ƒ“‚𓊗^’†‚Å‚ ‚邱‚Æ‚ðŽ¦‚·�B
MHA �Fƒ}ƒCƒNƒ�ƒ]�[ƒ€�R‘Ì�iTPOAb�j�ATA�FƒTƒCƒ�ƒOƒ�
ƒuƒŠƒ“�R‘Ì�iTGAb�j
6�jƒuƒ�ƒbƒLƒ“ƒO�R‘Ì�iTSBAb�j �Áޏ‚É”º‚¤‰Â‹t�«�b�ó‘B‹@”\ ’ቺ�Ç8�j
�@ƒuƒ�ƒbƒLƒ“ƒO�R‘ÌTSBAb �Á ޏ‚É”º‚¢�b�ó‘B‹@”\’ቺ�Ç‚©‚ç ‰ñ•œ‚·‚é�ǗႪ‚ ‚é�i�}5�j
7�jŒ´ˆö•s–¾‚̉‹t�«�b�ó‘B‹@ ”\’ቺ�Ç
�@Œ´ˆö•s–¾‚̉‹t�«�b�ó‘B‹@”\ ’ቺ�ǂ͑½‚¢10�j�B�b�ó‘Bƒzƒ‹ƒ‚ ƒ“•ž—p’†‚Ì–��«�b�ó‘B‰Š‚É‚æ‚é �b�ó‘B‹@”\’ቺ�ÇŠ³ŽÒ‚Ì1/5 ‚Í �b�ó‘Bƒzƒ‹ƒ‚ƒ“‚𒆎~‚·‚邱‚Æ ‚ª‚Å‚«‚é�B5�l‚É1�l‚Í�b�ó‘Bƒz ƒ‹ƒ‚ƒ“‚ð•s•K—v‚ɓЗ^‚³‚ê‚Ä‚¢ ‚é�B�b�ó‘Bƒzƒ‹ƒ‚ƒ““Š—^‚Í�S‹Ø �[�Ç�A‹·�S�Ç�AŽž‚É‚Í�œ‘eé �Ç ‚ðˆø‚«‹N‚±‚·‚±‚Æ‚ª‚ ‚é�B
�}5�Dƒuƒ�ƒbƒLƒ“ƒO�R‘Ì�Áޏ‚É”º‚¤‰Â‹t�«�b�ó‘B‹@”\’ቺ�Ç8�j
ƒuƒ�ƒbƒLƒ“ƒO�R‘ÌTSBAb —z�«‚ÌŽ©ŒÈ–Ɖu‚É‚æ‚é�b�ó‘B‹@”\’á‰ºŠ³ŽÒ21 —á
‚Ì10 ”N‚ɂ킽‚éŠÏŽ@�B21 —á’†�A�Ç—á1 �` 15�i‡TA�A‡TB�j‚Ì15 —á‚ÅTSBAb
�i‚±‚±‚Å‚ÍTBII�j‚Í�Áޏ‚µ‚½‚ª�A�Ç—á16 �` 21 ‚Ì6 —á‚Å‚ÍTBII ‚Í�‚’l‚̂܂Ü
‚Å‚ ‚Á‚½�B�Ç—á1 �` 6�i‡T A�j‚ÍTBII �Áޏ‚É”º‚¢�A�b�ó‘B‹@”\’ቺ�Ç‚©‚ç‰ñ
•œ‚µ‚½�B‰Â‹t�«�b�ó‘B‹@”\’ቺ�ǂł ‚Á‚½�B�Ç—á7 �` 21�i‡T B�A‡U�j‚Í�b
�ó‘B‹@”\’ቺ�ǂ̂܂܂ł ‚Á‚½�B‡U‚͈Þ�k�«�b�ó‘B‰Š‚Å�b�ó‘B‹@”\’ቺ�Ç
‚̂܂܂ł ‚é�BTBII, TSBAb ‚Í�í‚É—z�«�B
TBII �FTSH binding inhibitory IgG, TSBAb�FTSH-stimulation blocking Ab.
�œ�F�b�ó‘BŽî�i�{�j�A�›�F�b�ó‘BŽî�i�|�j�B
4�j‹´–{•a�b�ó‘B‹@”\’ቺ�Ç‚©‚ç ƒoƒZƒhƒE•a�b�ó‘B‹@”\˜´�i�Ç‚É�A ‚»‚µ‚Ävice versa2,15,16�j
ŽhŒƒ�R‘ÌTSAb ‚©‚çƒuƒ�ƒbƒLƒ“ ƒO�R‘ÌTSBAb�A‹t‚ÉTSBAb ‚©‚ç TSAb ‚ɂȂé�ǗႪ‚ ‚é2�j�BTRAb ‚ɂ͎hŒƒ�R‘ÌTSAb ‚ƃuƒ�ƒbƒLƒ“ ƒO�R‘ÌTSBAb ‚ª‚ ‚é�BTBII ‚Í TSAb ‚ÆTSBAb ‚ð‹æ•Ê‚µ‚È‚¢�B TSAb ‚ÆTSBAb ‚͂Ƃà‚ÉTSH Žó —e‘Ì�R‘ÌTRAb ‚Å‚ ‚é�BTSBAb ‚©‚çTSAb ‚É‘ã‚í‚é�ǗႪ‚ ‚é �i�}6�j�BTSBAb ‚É‚æ‚é�b�ó‘B‹@”\ ’ቺ�Ç‚©‚ç�AŽhŒƒ�R‘ÌTSAb ‚É‚æ ‚éƒoƒZƒhƒE•a‚ɂȂé—Ⴊ‚ ‚é�B‹t ‚ÉTSAb ‚©‚çTSBAb ‚ɂȂé�Ç—á ‚ª‚ ‚é�B
ƒoƒZƒhƒE•a‚Æ‹´–{•a‚Í�b�ó‘B‹@”\˜´�i�Ç‚Æ�b �ó‘B‹@”\’ቺ�ǂƕ\Œ»‚Í‹t‚Å‚ ‚邪�A“¯ˆêŒÂ�l ‚»‚µ‚ĉƑ°“à‚É”�Ç‚·‚é�BƒoƒZƒhƒE•a‚Æ‹´–{•a‚Í “¯ˆê‚̈â“`‚Ɗ‹«‚ð”wŒi‚É”�Ç‚·‚é�B‚ǂ̂悤‚È ‹@�˜‚ŃoƒZƒhƒE•a�b�ó‘B‹@”\˜´�i�Ç‚ ‚é‚¢‚Í‹´–{ •a�b�ó‘B‹@”\’ቺ�ǂɂȂ邩‚Í•s–¾‚Å‚ ‚é�B
�}6�Dƒuƒ�ƒbƒLƒ“ƒO�R‘ÌTSBAb ‚É‚æ‚é�b�ó‘B‹@”\’ቺ�Ç‚©‚çTSAb ‚É‚æ‚éƒoƒZƒhƒE
•a‚ɂȂÁ‚½—á2�j
44 �Î�—�«�Bƒuƒ�ƒbƒLƒ“ƒO�R‘ÌTSBAb ‚É‚æ‚é�b�ó‘B‹@”\’ቺ�Ç‚©‚çTSAb ‚É
‚æ‚éƒoƒZƒhƒE•a‚ɂȂÁ‚½�B
TSBAb �F TSH-stimulationblocking Ab, TSAb �F
thyroid stimulating Ab, TBII �F TSH binding inhibitory immunoglobulin,
MMI �F 1-methyl-2-mercapto-imidazole�iƒ�ƒ‹ƒJƒ]�[ƒ‹�j, T4 �F thyroxine.
‹´–{•a‚Ì�f’f‚Í‘g�D�f‚Å‚ ‚é1�j�B‚µ‚©‚µ�A‘S ‚Ä‚Ì�Ç—á‚Å‘g�D‚ð‚݂邱‚Ƃ͂ł«‚È‚¢�B TPOAb�ATGAb ‚ª—z�«‚Å�A�b�ó‘B‹@”\’ቺ�Ç ‚ª‚ ‚邯‚«�A‹´–{•a‚É‚æ‚é�b�ó‘B‹@”\’ቺ�Ç‚ð �l‚¦‚é�BTPOAb�ATGAb‚̓oƒZƒhƒE•a‚Ì TRAb �iTBII �ETSAb�j‚Ù‚ÇŠ´“x�E“ÁˆÙ“x‚ª —Ç‚‚͂Ȃ�A‹´–{•a‚ÌŽw•W‚É‚·‚¬‚È‚¢�B
‚Ü‚½ƒuƒ�ƒbƒLƒ“ƒO�R‘ÌTSBAb ‚Í�b�ó‘B‹@”\ ’ቺ�ǂ̌´ˆö‚Å‚ ‚é5,7,8,16�j�BTSBAb ‚͈Þ�k�«�b �ó‘B‰Š‚ÌŒ´ˆö‚Å‚ ‚é�B
•¶�@Œ£
1�jHashimoto H. Zur Kenntniss der lymphomatosen
Veranderung der Schilddruse�istruma lymphomatosa�j.
Arch Klin Chir 97 �F 219-248, 1912
2�jTakasu N, et al. Hashimoto�fs thyroiditis �F TGAb,
TPOAb, TRAb and recovery from hypothyroidism.
Expert Review of Clinical Immunology 4 �F 221-237,
2008
3�j�‚�{�M�s�@–��«�b�ó‘B‰Š�i‹´–{•a�j‘Ž�‡—Õ�°�@49 �F
2199-2204, 2000
4�jAkamine H, Takasu N, et al. Association of HTLV-I
with autoimmune thyroiditis in patients with adult Tcell
leukaemia �iATL�j and in HTLV-I carriers.
Clin Endocrinol �iOxf�j 45 �F 461-466, 1996
5�jTakasu N, et al. Evidence for thyrotropin �iTSH�j-
blocking activity in goitrous Hashimoto's thyroiditis
with assays measuring inhibition of TSH receptor
binding and TSH-stimulated thyroid adenosine 3',5'-
monophosphate responses/cell growth by
immunoglobulins. J Clin Endocrinol Metab 64 : 239-
245, 1987
6�j�‚�{�M�s�@�b�ó‘B‹@”\’ቺ�Ç�@‘Ž�‡—Õ�°56 �F 1587-1596, 2007
7�jTakasu N, et al.�F Transient neonatal hypothyroidism
due to maternal immunoglobulins that inhibit
thyrotropin-binding and post-receptor processes. J
Clin Endocrinol Metab 59 �F 142-146, 1984
8�jTakasu N, et al. Disappearance of thyrotropin-blocking
antibodies and spontaneous recovery from hypothyroidism
in autoimmune thyroiditis. N Engl J Med 326 �F 513-
518, 1992
9�j�‚�{�M�s�@‹´–{•a; �b�ó‘B‹@”\’ቺ�Ç‚Ì�f’f‚ÆŽ¡—Ã�A
‚»‚µ‚ĉ‹t�«�b�ó‘B‹@”\’ቺ�Ç. “ú–{“à‰ÈŠw‰ïŽGŽ�
86 �F 1147-1155, 1997
10�jTakasu N, et al. Test for recovery from hypothyroidism
during thyroxine therapy in Hashimoto's thyroiditis.
Lancet 336�i8723�j�F 1084-1086, 1990
11�jTakasu N, et al. Rifampin-induced hypothyroidism in
patients with Hashimoto's thyroiditis. N Engl J Med
352 �F 518-519, 2005
12�jTakasu N, et al. Rifampin-induced hypothyroidism. J
Endocrinol Invest 29 �F 645-649, 2006
13�jTakasu N, et al. Exacerbation of autoimmune thyroid
dysfunction after unilateral adrenalectomy in patients
with Cushing's syndrome due to an adrenocortical
adenoma. N Engl J Med 322 �F 1708-1712, 1990
14�jTakasu N, et al. Development of autoimmune thyroid
dysfunction after bilateral adrenalectomy in a patient
with Carney's complex and after removal of ACTHproducing
pituitary adenoma in a patient with
Cushing's disease. J Endocrinol Invest 16 �F 697-702,
1993
15�jTakasu N, et al. Graves' disease following hypothyroidism
due to Hashimoto's disease �F studies of eight cases.
Clin Endocrinol �iOxf�j 33 �F 687-98, 1990
16�jTakasu N, et al. TSBAb �iTSH-stimulation blocking
antibody�j and TSAb �ithyroid stimulating antibody�j
in TSBAb-positive patients with hypothyroidism and
Graves' patients with hyperthyroidism. Horm Metab
Res 33 �F 232-337, 2001
ƒL�[ƒ��[ƒh
�b�ó‘BŽ©ŒÈ–Ɖu޾г�AƒoƒZƒhƒE•a�A‹´–{•a�A–��«�b�ó
‘B‰Š�A�b�ó‘B‹@”\’ቺ�Ç�A�b�ó‘Bƒzƒ‹ƒ‚ƒ“�A‰Â‹t�«�b
�ó‘B‹@”\’ቺ�Ç�Aˆê‰ß�«�b�ó‘B‹@”\’ቺ�Ç�ATSH Žó
—e‘Ì�R‘Ì�i T R A b �j�A�b�ó‘Bƒuƒ�ƒbƒLƒ“ƒO�R‘Ì
�iTSBAb�j�A�b�ó‘BŽhŒƒ�R‘Ì�iTSAb�j�Aƒˆ�[ƒh�AƒŠƒt
ƒ@ƒ“ƒsƒVƒ“�AƒNƒbƒVƒ“ƒO�ÇŒóŒQ
’˜�@ŽÒ�@�Ð�@‰î
![]()
—®‹…‘åŠwˆãŠw•”�@‘æ“ñ“à‰È‹³Žö
ûü�{�@�M�s�o�g’n�Fˆ¤’mŒ§
�o�g‘åŠw�F“Œ‹žˆã‰ÈŽ•‰È‘åŠw
—ª—ð
Œ»�Ý�@—®‹…‘åŠwˆãŠw•”�@‘æ“ñ“à‰È‹³Žö
“Œ‹žˆã‰ÈŽ•‰È‘åŠw‘²‹Æ�Aƒtƒ‰ƒ“ƒX�‘—§‰q�¶Œ¤‹†�Š
Œ¤‹†Žå”C�A�M�B‘åŠwˆãŠw•”�•‹³Žö�ê�U�E�f—×̈æ
�@�b�ó‘B�E“à•ª”å�E“œ”A•a�E‘ãŽÓ‚»‚Ì‘¼�EŽï–¡“™
�@ŽR“o‚è�A�…‰j�A“Ç�‘�AŽG•¶‚ð�‘‚‚±‚Æ�B
–â‘è�FˆÈ‰º‚Ì‹L�q‚Å�³‚µ‚¢‚̂͂ǂꂩ�BŽO‚ ‘I‚×�B
• �o‹¾�i•â�•�j‰º‚ÌŠÌ�Ø�œ�p‚¨‚æ‚у‰ƒW ƒI”g�ÄŽÜ�p
–â‘è�F• �o‹¾�i•â�•�j‰ºŠÌ�Ø�œ�p‚ÉŠÖ‚·‚鎟‚Ì ‹L�q‚Ì’†‚©‚ç�³‚µ‚¢‚à‚Ì‚ð‘I‘ð‚¹‚æ�B
�³‰ð�@3